JP Morgan Chase
BBC icon

JP Morgan Chase’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

JP Morgan Chase’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-183
Closed -$6K – 5541
2018
Q1 		$6K Buy
+183
New +$5.97K ﹤0.01% 5222

Other funds holding BBC

NCM
Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase's BBC Position: Q2 2018 in Review

JP Morgan Chase sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2018, closing a stake of 183 shares — an estimated $6K sold.

JP Morgan Chase first reported a position in BBC in Q1 2018 and held it in 1 quarter. The position peaked at $6K in Q1 2018. 19 funds tracked by Wall St. Rank hold BBC as of Q2 2018.

  • JP Morgan Chase reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2018 after selling out during the quarter.
  • JP Morgan Chase sold 183 Virtus Biotech Clinical Trials ETF shares in Q2 2018, an estimated $6K.
  • JP Morgan Chase first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2018 and held it in 1 quarter.
  • JP Morgan Chase's Virtus Biotech Clinical Trials ETF position peaked at $6K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2018.

Based on JP Morgan Chase's 13F filing for Q2 2018, filed 14 Aug 2018.